Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 10:54:48 2024-04-18 am EDT			5-day change	1st Jan Change
85.43 ^EUR	-0.87%		-1.42%	-4.81%

01:53pm	SANOFI : JP Morgan reiterates its Neutral rating	ZD
01:00pm	Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger	CI

SANOFI : Receives a Buy rating from Goldman Sachs

January 25, 2023 at 03:51 am EST

Keyur Parekh from Goldman Sachs retains his positive opinion on the stock with a Buy rating. The target price is revised downwards from EUR 134 to EUR 128.

Latest news about Sanofi

SANOFI : JP Morgan reiterates its Neutral rating	07:53am	ZD
Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger	07:00am	CI
IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	Apr. 17	MT
BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Sanofi's Frexalimab Reduces Disease Activity in Multiple Sclerosis Patients in Phase 2 Trial	Apr. 17	MT
Sanofi: new positive phase II results in MS	Apr. 17	CF
IDT Australia Signs Master Service Agreement with Sanofi	Apr. 15	MT
Sanofi: progress in hematology trial	Apr. 15	CF
Innate Pharma: progress in hematology trial	Apr. 15	CF
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says	Apr. 12	DJ
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs	Apr. 12	MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts	Apr. 12	RE
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration	Apr. 09	DJ
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate	Apr. 09	MT
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	Apr. 09	CI
Sanofi Launches Rabies Vaccine in the UK	Apr. 05	MT
Sanofi: rabies vaccine launched in the UK	Apr. 05	CF
Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups	Apr. 05	CI
SANOFI : Gets a Buy rating from Barclays	Apr. 04	ZD
News Highlights : Top Company News of the Day - Thursday at 7 AM ET	Apr. 04	DJ
European Midday Briefing : Investors Cheer Reassuring Powell, Encouraging Data	Apr. 04	DJ
News Highlights : Top Company News of the Day - Thursday at 5 AM ET	Apr. 04	DJ
News Highlights : Top Company News of the Day - Thursday at 3 AM ET	Apr. 04	DJ
European stocks rise ahead of inflation data; Basilea shines	Apr. 04	RE
News Highlights : Top Company News of the Day - Thursday at 1 AM ET	Apr. 04	DJ

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

CAC 40 , EURO STOXX 50 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANOFI : Looking beyond the quarterly miss, Sanofi remains an attractive bet

February 01, 2024 at 11:26 am EST

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

86.18 EUR

Average target price

107.5 EUR

Spread / Average Target

+24.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	-4.81%	114B
ELI LILLY AND COMPANY	+28.84%	676B
NOVO NORDISK A/S	+24.29%	554B
JOHNSON & JOHNSON	-7.34%	349B
MERCK & CO., INC.	+14.50%	318B
ABBVIE INC.	+7.82%	291B
ASTRAZENECA PLC	+3.19%	210B
NOVARTIS AG	-0.32%	204B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : Receives a Buy rating from Goldman Sachs

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals